NCT03993210

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting and Q-space Trajectory Imaging in gynecological abnormalities. The purpose of this research study is to evaluate if these new MRI methods can give additional information in characterizing gynecological tumors compared with conventional MRI.

Detailed description

Magnetic resonance imaging (MRI) is a safe and painless test that uses a magnetic field and radio waves to produce detailed images of the body's organs and structures. This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) in gynecological abnormalities. The purpose of this research study is to evaluate if these new MRI methods can give additional information in characterizing gynecological tumors compared with conventional MRI In this research study, the investigators are: * Investigating the use of MR imaging in gynecological tumors on imaging quality and comparison of tumor or fibroid structures and normal anatomy * Investigating whether new MRI methods could help in characterizing the tumor and give information about the expected outcome

Conditions

• Gynecologic Tumor

Interventions

Type	Name	Description
DEVICE	Magnetic Resonance Fingerprinting (MRF)	In MRF, multiple tissue properties are acquired simultaneously.
DEVICE	Q-space Trajectory Imaging (QTI)	By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
DEVICE	Magnetic Resonance Imaging Machine (MRI)	MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.

Timeline

• Start date: 2019-09-18
• Primary completion: 2019-09-19
• Completion: 2019-09-19
• First posted: 2019-06-20
• Last updated: 2020-12-02
• Results posted: 2020-12-02

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated device study